{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:54:09Z","timestamp":1794012849191,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.semarthrit.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T04:00:53Z","timestamp":1594785653000},"page":"1073-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"50","author":[{"given":"Lanlan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.07.006_bib0001","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0002","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(18)30544-0","article-title":"CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematosus","volume":"391","author":"Fernandez","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0003","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0004","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"V\u00e9zina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: one drug, many effects","volume":"19","author":"Li","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0007","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(89)90417-0","article-title":"Rapamycin for immunosuppression in organ allografting","volume":"2","author":"Calne","year":"1989","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0008","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/art.1780370219","article-title":"Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus","volume":"37","author":"Warner","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0009","first-page":"2063","article-title":"Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1\/Rab4-regulated lysosomal degradation","volume":"182","author":"Fernandez","year":"2009","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0010","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.22085","article-title":"Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0011","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fphar.2019.00082","article-title":"Clinical experience of Sirolimus regarding efficacy and safety in systemic lupus erythematosus","volume":"10","author":"Eriksson","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0013","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/0961203319877239","article-title":"Restoring T-helper 17 cell\/regulatory T-cell balance and decreasing disease activity by rapamycin and all-trans retinoic acid in patients with systemic lupus erythematosus","volume":"28","author":"Chu","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0014","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1749-6632.2009.04663.x","article-title":"Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option","volume":"1173","author":"Yoon","year":"2009","journal-title":"Ann N Acad Sci"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0016","doi-asserted-by":"crossref","first-page":"e12631","DOI":"10.1111\/dth.12631","article-title":"Rapamycin for refractory discoid lupus erythematosus","volume":"31","author":"Herold","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0017","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3899\/jrheum.180507","article-title":"Longterm data on Sirolimus treatment in patients with Lupus Nephritis","volume":"45","author":"Yap","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0018","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/annrheumdis-2019-eular.7068","article-title":"Sirolimus in patients with systemic lupus erythematosus related thrombocytopenia (SLE-TP): a single-arm, open-label clinical trial","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0019","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","article-title":"Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors","volume":"31","author":"Gasparyan","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0021","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/rheumatology\/ket169","article-title":"The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis","volume":"52","author":"Matcham","year":"2013","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","article-title":"Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study","volume":"86","author":"Iaccarino","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0023","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1177\/0961203313499086","article-title":"Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus","volume":"22","author":"Li","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0024","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0025","first-page":"1721","article-title":"Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis","volume":"133","author":"Zhang","year":"2019","journal-title":"Clin Sci Lond Engl 1979"},{"issue":"Suppl 122","key":"10.1016\/j.semarthrit.2020.07.006_bib0026","first-page":"13","article-title":"Is sirolimus a treatment option for patients with systemic lupus erythematosus?","volume":"37","author":"Esatoglu","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0027","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/art.21029","article-title":"An international cohort study of cancer in systemic lupus erythematosus","volume":"52","author":"Bernatsky","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0028","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.2006.069039","article-title":"The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study","volume":"67","author":"Bernatsky","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0029","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/cam4.487","article-title":"Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis","volume":"4","author":"Yanik","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0030","first-page":"813","article-title":"Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation","volume":"42","author":"Nguyen","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0031","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.transproceed.2006.01.044","article-title":"Side effects of Sirolimus","volume":"38","author":"Merkel","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.semarthrit.2020.07.006_bib0032","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:05:44Z","timestamp":1758733544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0049017220302080"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.07.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}